Enliven Therapeutics, Inc. - ELVN
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| May 15, 2026 | SCHEDULE 13G/A | Polar Capital Holdings Plc | 8.46% | 5,056,807 | View |
| May 15, 2026 | SCHEDULE 13G/A | Polar Capital LLP | 8.46% | 5,056,807 | View |
| May 15, 2026 | SCHEDULE 13G/A | Polar Capital Funds PLC - Biotechnology Fund | 8.46% | 5,056,807 | View |
| May 15, 2026 | SCHEDULE 13G/A | Vestal Point Capital, LP | 5.4% | 3,250,000 | View |
| May 15, 2026 | SCHEDULE 13G/A | Ryan Wilder | 5.4% | 3,250,000 | View |
| May 15, 2026 | SCHEDULE 13G/A | Fairmount Funds Management LLC | 3.1% | 1,855,644 | View |
| May 15, 2026 | SCHEDULE 13G/A | Fairmount Healthcare Fund II L.P. | 3.1% | 1,855,644 | View |
| May 15, 2026 | SCHEDULE 13G/A | Peter Harwin | 3.1% | 1,855,644 | View |
| May 15, 2026 | SCHEDULE 13G/A | Kiselak Tomas | 3.1% | 1,855,644 | View |
| May 15, 2026 | SCHEDULE 13G/A | Venrock Healthcare Capital Partners III, L.P. | 2.8% | 1,726,331 | View |
| May 15, 2026 | SCHEDULE 13G/A | VHCP Co-Investment Holdings III, LLC | 2.8% | 1,726,331 | View |
| May 15, 2026 | SCHEDULE 13G/A | Venrock Healthcare Capital Partners EG, L.P. | 2.8% | 1,726,331 | View |
| May 15, 2026 | SCHEDULE 13G/A | VHCP Management III, LLC | 2.8% | 1,726,331 | View |
| May 15, 2026 | SCHEDULE 13G/A | VHCP Management EG, LLC | 2.8% | 1,726,331 | View |
| May 15, 2026 | SCHEDULE 13G/A | Nimish Shah | 2.8% | 1,726,331 | View |
| May 15, 2026 | SCHEDULE 13G/A | Bong Y. Koh | 2.8% | 1,726,331 | View |
| May 15, 2026 | SCHEDULE 13G/A | Commodore Capital LP | 7.7% | 4,800,940 | View |
| May 15, 2026 | SCHEDULE 13G/A | Commodore Capital Master LP | 7.7% | 4,800,940 | View |
| May 15, 2026 | SCHEDULE 13G/A | Robert Egen Atkinson | 7.7% | 4,800,940 | View |
| May 15, 2026 | SCHEDULE 13G/A | Michael Kramarz | 7.7% | 4,800,940 | View |
| May 15, 2026 | SCHEDULE 13G/A | Polar Capital Holdings Plc | 8.47% | 59,800,406 | View |
| May 15, 2026 | SCHEDULE 13G/A | Polar Capital LLP | 8.47% | 59,800,406 | View |
| May 15, 2026 | SCHEDULE 13G/A | Polar Capital Funds PLC - Biotechnology Fund | 8.47% | 59,800,406 | View |
| Feb 17, 2026 | SCHEDULE 13G | Vestal Point Capital, LP | 6.5% | 3,830,000 | View |
| Feb 17, 2026 | SCHEDULE 13G | Ryan Wilder | 6.5% | 3,830,000 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.